Thomas Schlake

USPTO Granted Patents = 32 (Patent Applications = 19)

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 18 (Patent Applications = 28)

Average Co-Inventor Count = 2.7

ph-index = 21

Forward Citations = 764(Granted Patents)

Location History:

Gundelfingen, DE (2008 - 2023)
Tübingen, DE (2023)

Company Filing History:

Max-planck-gesellschaft Zur Förderung Der Wissenschaften E. V.

patents

Years Active: 2008-2025

Loading Chart...

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12442005 - Artificial nucleic acid molecules for improved protein expression (2025-10-14),

2. 12371699 - Nucleic acids encoding CRISPR-associated proteins and uses thereof (2025-07-29),

3. 12258567 - Artificial nucleic acid molecules (2025-03-25),

4. 12201680 - Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen (2025-01-21),

5. 12109275 - Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein (2024-10-08),

6. 11761009 - Artificial nucleic acid molecules for improved protein expression (2023-09-19),

7. 11739335 - Nucleic acids encoding CRISPR-associated proteins and uses thereof (2023-08-29),

8. 11697816 - Artificial nucleic acid molecules (2023-07-11),

9. 11345920 - Artificial nucleic acid molecules for improved protein expression (2022-05-31),

10. 11286492 - Artificial nucleic acid molecules for improved protein expression (2022-03-29),

11. 11149278 - Artificial nucleic acid molecules for improved protein expression (2021-10-19),

12. 11110156 - Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen (2021-09-07),

13. 10912826 - Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen (2021-02-09),

14. 10898589 - Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein (2021-01-26),

15. 10898584 - Modified RNA with decreased immunostimulatory properties (2021-01-26),

Title: Innovations and Contributions of Thomas Schlake in Biotechnology

Introduction: Thomas Schlake, an accomplished inventor based in Gundelfingen, Germany, is recognized for his significant contributions to biotechnology, particularly in the development of nucleic acid-based technologies. With an impressive portfolio of 29 patents, Schlake has focused on enhancing the expression of pathogenic antigens for pharmaceutical applications.

Latest Patents: Among his latest inventions, Schlake’s research includes nucleic acid sequences comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal aimed at increasing the expression of encoded peptides or proteins. His first patent relates to using this nucleic acid sequence to boost the expression of pathogenic antigens, with a specific focus on preparing pharmaceutical compositions such as vaccines for treating infectious diseases. Additionally, another patent highlights similar methodologies for producing pharmaceutical compositions for various medical conditions including tumors, cancer, cardiovascular diseases, autoimmune diseases, and genetic diseases, as well as applications in gene therapy.

Career Highlights: Throughout his career, Thomas Schlake has held key positions in renowned companies, notably CureVac AG and CureVac SE. His expertise in biotechnology has allowed him to lead impactful projects that leverage innovative solutions in the field. These positions have played a vital role in the advancement of molecular medicine and vaccine development.

Collaborations: Thomas Schlake has collaborated with esteemed colleagues, including Andreas Thess and Jochen Probst, which has facilitated the exchange of ideas and fostered innovative thinking. These collaborations have significantly contributed to the success of his ventures in the biotechnology sector.

Conclusion: Thomas Schlake is a prominent figure in the realm of biotechnology, with a strong focus on nucleic acid technology and its applications in medicine. His extensive patent portfolio underscores his dedication to advancing scientific knowledge and addressing critical health challenges through innovative solutions. As he continues to push the boundaries of research, Schlake remains an influential inventor whose work will significantly impact future medical advancements.

This text is generated by artificial intelligence and may not be accurate.